C2MI Nucleotide Sequences for Early Disease Marker Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively identify specific nucleotide sequences associated with diseases such as cancer, atherosclerosis, diabetes, and CNS disorders, limiting diagnostic and therapeutic options.
Innovation Solution
Isolation and analysis of circular DNA genomes from cow milk samples using abutting PCR primers to amplify full-length circular DNA molecules, identifying C2MI sequences with similarity to plasmids of Acinetobacter baumannii, which are used as markers for disease diagnosis and potential therapeutic targets.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional metagenomic analysis methods are used to identify infectious agents, then known agents can be detected, but novel or unknown infectious agents remain unidentified
Solution Approach 1:
The patent applies preliminary action by performing in silico comparisons and metagenomic analyses before actual sample testing to identify potential novel infectious agents. This preparatory computational work enables the detection of unknown agents by establishing reference frameworks and identification criteria in advance, resolving the contradiction between reliable detection of known agents and the ability to discover novel ones.
2Reliability
If focus is placed on identifying known infectious entities, then detection reliability is maintained, but identification of novel infectious agents is neglected
Solution Approach 1:
The patent applies parameter changes by modifying the analytical parameters of metagenomic studies - shifting from traditional targeted detection of known agents to broader genomic sequencing and comparison parameters that capture novel infectious entities. This includes using updated databases, expanded taxonomic coverage, and modified identification thresholds, enabling simultaneous maintenance of reliable known agent detection while discovering novel pathogens.
3Device complexity
If strict demarcation between infectious agent groups is maintained, then classification clarity is preserved, but phylogenetic relationships and chimeric genomes cannot be properly analyzed
Solution Approach 1:
The patent applies segmentation by dividing the analysis into distinct functional modules: genomic sequencing, in silico comparison, phylogenetic tree construction, and chimeric genome detection. This segmented approach allows clear classification of known agents while simultaneously enabling complex phylogenetic analyses and identification of chimeric genomes, resolving the contradiction between classification simplicity and analytical versatility.
Data Source
AI summary
Described are CMI (Cow Milk Isolate) nucleotide sequences as well as probes and primers comprising part of said nucleotide sequences and antibodies against polypeptides encoded by said nucleotide sequences. Said compounds are useful as early markers for the future development of cancer, diabetes, atherosclerosis and diseases of the CNS (Multiple sclerosis MS, Prion-linked diseases, amyotrophic lateral sclerosis, transmissible spongiforme encephalitis, Parkinson's disease, Alzheimer disease) and should represent targets for treatment and prevention.